Table 2.

Univariate and multivariate analyses of progression-free survival

	Number of patients		Univariate			Multivariate
Parameter	Yes	No	HR	95% CIs	P value	HR	95% CIs	P value
Age < 58 yo	23/51	28/51	2.440	1.120–5.316	0.0248	0.315	0.074–1.467	0.1367
Estrogen receptor positive (vs. negative)	23/51	28/51	1.198	0.555–2.588	0.6448
Progesterone receptor positive (vs. negative)	11/51	40/51	1.177	0.456–3.040	0.7361
HER2 3+	40/51	11/51	1.421	0.558–3.618	0.5431
Non-visceral metastases (vs. visceral)	32/51	19/51	0.926	0.429–1.996	0.8441
Eribulin (vs. Nab-PTX)	30/51	21/30	1.593	0.751–3.378	0.2249
Prior treatment < 3 line	30/51	21/30	0.401	0.185–0.870	0.0208	0.528	0.234–1.157	0.1106
Absolute lymphocyte count ≥ 1000/uL	37/51	14/51	0.308	0.133–0.714	0.0061	0.735	0.284–1.770	0.4977
Absolute lymphocyte count ≥ 1500/uL	19/51	32/51	0.372	0.174–0.796	0.0108	0.296	0.098–0.794	0.0150
Neutrophil to lymphocyte ratio > 2	31/51	20/51	2.109	0.985–4.516	0.0548
Platelet to lymphocyte ratio > 150	31/51	20/51	2.038	0.962–4.318	0.0632